Pernicious Anemia: Multiple Autoimmune Mechanisms Beyond Classic Gastritis
Breakthrough research reveals why 40–60% of pernicious anemia patients test negative for intrinsic factor antibodies yet still require lifelong B12 therapy. These discoveries identify multiple autoimmune mechanisms affecting B12 absorption and utilization—some involving autoimmune gastritis through non-antibody pathways, others targeting completely different parts of the B12 system. The findings fundamentally expand our understanding of pernicious anemia as a spectrum of autoimmune B12 disorders rather than a single gastric disease.
Recent molecular discoveries have identified anti-CD320 receptor autoantibodies as a major cause of “autoimmune B12 central deficiency,” where patients develop selective nervous system B12 deficiency despite normal serum levels. Combined with genetic studies revealing five risk loci and emerging understanding of T-cell–mediated gastric destruction, these findings reshape the clinical approach to antibody-negative cases. This research demonstrates that pernicious anemia encompasses diverse autoimmune mechanisms affecting multiple points in B12 metabolism, explaining both gastritis-related and non-gastritis forms of the condition.
